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Background: Although prompt reperfusion treatment restores normal epicardial flow, microvascular dysfunction may
persist in some patients with acute coronary syndrome (ACS). Impaired myocardial perfusion is caused by intraluminal
platelets, fibrin thrombi and neutrophil plugging; antiplatelet agents play a significant role in terms of protecting
against thrombus microembolization. A novel antiplatelet agent, ticagrelor, is a non-thienopyridine, direct P2Y12
blocker that has shown greater, more rapid and more consistent platelet inhibition than clopidogrel. However, the
effects of ticagrelor on the prevention of microvascular dysfunction are uncertain. The present study is a comparison
between clopidogrel and ticagrelor use for preventing microvascular dysfunction in patients with ST elevation or
non-ST elevation myocardial infarction (STEMI or NSTEMI, respectively).
Methods/design: The TIME trial is a single-center, randomized, open-label, parallel-arm study designed to demonstrate
the superiority of ticagrelor over clopidogrel. A total of 152 patients with a spectrum of STEMI or NSTEMI will undergo
prospective random assignment to clopidogrel or ticagrelor (1:1 ratio). The primary endpoint is an index of
microcirculatory resistance (IMR) measured after percutaneous coronary intervention (PCI); the secondary endpoint is
wall motion score index assessed at 3 months by using echocardiography.
Discussion: The TIME trial is the first study designed to compare the protective effect of clopidogrel and ticagrelor on
coronary microvascular dysfunction in patients with STEMI and NSTEMI.
Trial registration: ClinicalTrials.gov: NCT02026219. Registration date: 24 December 2013.
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The novel antiplatelet agents, prasugrel and ticagrelor,
have overcome many of the pharmacodynamic limitations
of clopidogrel and have improved outcomes in patients
with acute coronary syndrome (ACS) [1,2].
Ticagrelor is a non-thienopyridine, direct P2Y12 blocker
that is more potent than clopidogrel and is associated with
less inter-individual variability. In the PLATO trial, it
was found to be superior to clopidogrel with respect to* Correspondence: denki1@inha.ac.kr
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unless otherwise stated.cardiovascular outcomes and total mortality without
increasing the risk of bleeding [2].
Faster onset of action and more potent and reversible
receptor bindings are possible explanations for the super-
ior outcomes of ticagrelor [3]. In addition to the potent
inhibition of platelet function, ticagrelor has previously
been shown to increase adenosine levels by inhibiting
adenosine re-uptake at the tissue level and inducing
adenosine triphosphate (ATP) release from human red
blood cells, which stimulate vasodilation [4]. A recent
study confirmed that ticagrelor increased adenosine plasma
concentration in patients with ACS when compared with
clopidogrel [5].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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developed, involving intraluminal platelets, fibrin thrombi,
neutrophil plugging, vasoconstriction, myocyte contracture,
local interstitial edema and intramural hemorrhage [6-8],
antiplatelet agents have been used as a basic medication for
protecting against microvascular dysfunction [9,10].
However, there has been no data on the role of higher
plasma adenosine and stronger inhibition of platelets in the
protection against microvascular dysfunction in ST eleva-
tion or non-ST elevation myocardial infarction (STEMI or
NSTEMI, respectively). Thus, we have designed a clinical
study that will compare the protective effect of ticagrelor
and clopidogrel on microvascular dysfunction in patients
with STEMI and NSTEMI. In our study, microvascular
dysfunction will be assessed by using the index of microcir-
culatory resistance (IMR), which correlates closely with
microvascular damage in myocardial infarction [11].
Methods
Study design
The TIME trial is a single-center, randomized, open-label,
parallel-arm study designed to demonstrate the superiority
of ticagrelor compared with clopidogrel treatment in pre-
venting microvascular dysfunction in patients with STEMI
and NSTEMI.
The protocol of the trial has been registered at
ClinicalTrials.gov (NCT02026219), and a brief flowchart
of the entire study is summarized in Figure 1. The sched-
ule of events for this trial is described in Table 1.
Endpoints
The primary endpoint of the study is an IMR mea-
sured immediately after index percutaneous coronaryFigure 1 TIME trial algorithm. Non-STEMI, non-ST-segment elevation
myocardial infarction; PCI, percutaneous coronary intervention; STEMI,
ST-segment elevation myocardial infarction.intervention (PCI). The secondary endpoint is the
echocardiographic finding of left ventricular wall mo-
tion score index at 3 months after the index PCI.
Patient population
We will enroll 152 patients, comprising 76 patients in
the ticagrelor group and 76 patients in the clopidogrel
group. Patients of at least 18 years of age, who have STEMI
or NSTEMI with documented ischemia due to a significant
lesion in a native coronary artery, will be included in this
study. All inclusion and exclusion criteria are summarized
in Appendix A and Appendix B, respectively.
If all the inclusion criteria are met and none of the
exclusion criteria apply, the patients will be asked to
provide written informed consent, as required by the
institutional review board and in accordance with the
Declaration of Helsinki.
Randomization and interventions
After the patients are enrolled, drug randomization will
be performed by using a random number table that will
be independently managed at the Inha University Hospital
Cardiovascular Research Center (Incheon, South Korea).
Percutaneous coronary intervention (PCI)
After random assignment to clopidogrel or ticagrelor
treatment, the index PCI procedure must be carried out
on all patients within 48 hours. All patients will receive
300 mg aspirin and a loading dose of 600 mg clopidogrel
or 180 mg ticagrelor before the procedure, unless the
patient has been taking one of these medications for
at least 1 week prior to the procedure. Unfractionated
heparin will be administered intravenously in boluses to
maintain an activated clotting time of >250 seconds dur-
ing the procedure. Administration of glycoprotein IIb/
IIIa inhibitors will be based on the physician’s discretion.
PCI will be performed according to current international
guidelines. The goals of the procedure are to achieve op-
timal angiographic efficacy of PCI at the infarct-related
artery and minimize the risk of procedure-related com-
plications. A full range of commercially available guiding
catheters, balloon catheters and guide wires will be readily
available.
Index of microcirculatory resistance (IMR) measurements
IMR measured at the infarct-related artery after primary
PCI is a strong predictor of myocardial damage [11] and
will provide a quantitative assessment of microvascular
dysfunction in ACS patients [12]. We plan to assess the
microvascular dysfunction using IMR measured at the
infarct-related artery immediately after reperfusion therapy.
The IMR will be assessed immediately after index PCI by
using methods described previously [13,14]. An intracor-
onary combined pressure-temperature sensor-tipped guide




30 days 3 months
± 2 weeks ± 1 month
Medical/clinical history (age, sex, risk factors, clinical diagnosis, angina status, cardiac history) X
Informed consenta X
Inclusion/exclusion criteria X
Brief physical examination X
Vital status X X X
Weight, height X




Electrolytes, LFT X X
Creatinine, BUN X X
hs-CRP X X
Fasting plasma triglycerides, HDL cholesterol, total cholesterol X X
Fasting glucose leveld X X
HbA1ce X X
Medications X X X
CK, CK-MB, troponin If X X
proBNP X X
Echocardiography X X
aThe informed consent will be signed either prior to or after the diagnostic angiogram; badditional ECGs will be performed at 60 ± 30 minutes post-procedure.
ECG at follow-up visits will only be obtained when clinically indicated by symptoms such as recurrent chest pain, ischemia or significant arrhythmias, heart failure
or other signs or symptoms of clinical instability; croutine follow-up angiography will be recommended at 9 months, but it can be performed at 9 months ± 2
months. Unscheduled angiograms ≥6 months after index procedure will be considered as the 9-month follow-up angiogram in final analysis; dmight be measured
later, before discharge, when the patient is in a fasting state; ewill be performed in patients with diagnosed diabetes mellitus; fcardiac enzyme levels should be
followed up for at least 24 hours in patients with symptoms such as recurrent chest pain, ischemia, significant arrhythmias, heart failure or other clinical signs or
symptoms of cardiac instability. Otherwise, the decision is up to the operator. If follow-up is performed, enzyme levels must be measured every 8 hours for at least
24 hours post-index procedure. BUN, blood urea nitrogen; CBC, complete blood count; CK, creatine kinase; ECG, electrocardiogram; HbA1c, hemoglobin A1c; HDL,
high-density lipoprotein; hs-CRP, high sensitivity C-reactive protein; IMR, index of microcirculatory resistance; LFT, liver function test; pro-BNP, pro-brain natriuretic peptide.
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Sweden) will be used to measure the thermodilution-
derived IMR and fractional flow reserve (FFR). The pres-
sure sensor will be placed at the distal two-thirds of the
infarct-related artery. Intracoronary nitroglycerine will be
administered (200 μg). Hyperemia will be induced by using
an adenosine infusion (140 μg/kg⋅min) administered via
the femoral or antecubital vein. Aortic and distal coronary
pressures will be measured during hyperemia, and the
FFR will be calculated by using the formula: FFR =Distal
coronary pressure/Aortic pressure. The IMR will be calcu-
lated from the ratio of the mean distal coronary pressure at
maximal hyperemia to the inverse of the hyperemic mean
transit time (Tmn) as follows: IMR =Distal pressure ×Tmn
during hyperemia [13,15]. Vessels with severe stenosis
(distal coronary pressure ≤60 mmHg) and collateral flow
will be excluded from the analysis because of the effect of
collateral flow [16,17].Post-PCI medication
All patients included in this trial will be treated according
to the current American College of Cardiology (ACC)/
American Heart Association (AHA) guidelines regarding
post-stenting management, which specify treatment with
at least 100 mg of aspirin daily, and 75 mg clopidogrel or
90 mg ticagrelor daily for at least 12 months after PCI.
Follow-up
Clinical follow-up will be performed at specified time
points (Table 1). Follow-ups should be office visits, but
telephone contact will be allowed. Data collected during
all follow-up visits will include angina class and the pres-
ence of major adverse ischemic, neurologic or bleeding
events, including re-hospitalization, re-catheterization and
adverse events/serious adverse events (SAEs). Original
source documents must be submitted for any clinical
events (death, reinfarction, revascularization, stroke or any
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readmitted to a non-study hospital, all possible efforts
should be made to obtain original source documents from
that hospital. For all reinfarctions, ECGs and cardiac en-
zymes (creatine kinase (CK), CK-MB and troponin) must
be obtained and recorded.
Sample size calculation
The objective is to determine whether ticagrelor is su-
perior to clopidogrel in preventing microvascular dys-
function in patients with STEMI or NSTEMI. Based on
previous reports for IMR values in STEMI and NSTEMI
[11,18,19], we will assume that the mean IMR in the clo-
pidogrel group is approximately 30 U with a standard
deviation of 20 U. To demonstrate that ticagrelor is su-
perior to clopidogrel, we will assume a reduction in IMR
of more than 10 U. Taking into account a drop-out rate
of 20% of the randomized patients, we will need 152
patients, comprising 76 in the ticagrelor group and 76 in
the clopidogrel group, with 80% power to detect a group
difference of 10 U in the change of the IMR value at a
two-sided alpha-level of 0.05.
Statistical analyses
All primary and secondary endpoints will be analyzed
both on an intention-to-treat basis (all patients analyzed
as part of their assigned treatment group) and on a per
protocol basis (patients analyzed as part of their assigned
treatment group only if they actually received their
assigned treatment).
Multivariate predictors of all primary and secondary
endpoints will be determined by using multivariate re-
gression models. Forward stepwise selection algorithms
will be used to select independent predictors. Baseline
characteristics of study patients will be summarized in
terms of frequencies and percentages for categorical var-
iables and by using means with standard deviations for
continuous variables. Categorical variables will be com-
pared by using Fisher’s exact test. Continuous variables
will be compared by using the two-sample t-test. A P value
of 0.05 will be established as the level of statistical signifi-
cance for all tests. Major subgroup analyses of the primary
and major secondary endpoints will be performed, in-
cluding patients with diabetes mellitus, advanced age
(age ≥70 years) and the diagnosis (STEMI or NSTEMI).
Trial organization
Executive committee
The executive committee will comprise the study chair-
person and the principal investigators of the investigat-
ing center. This committee will approve the final trial
design and protocol that will be issued to the Data and
Safety Monitoring Board (DSMB) and the clinical site.
This committee will also be responsible for reviewingthe final results, determining the methods of presentation
and publication, and the selection of secondary projects
and publications by members of the steering committee.
Data Safety Monitoring Board (DSMB)
The DSMB is composed of general and interventional
cardiologists. The DSMB will function in accordance
with applicable regulatory guidelines. The board mem-
bers are independent and will not be participating in the
trial. The DSMB committee will review the safety data
from this study, and make recommendations based on
safety analyses of unanticipated device effects, SAEs,
protocol deviation, device failures and 30-day follow-up
reports. The frequency of the DSMB meetings will be
determined prior to study commencement. Additionally,
the DSMB may call a meeting at any time if there is
reason to suspect that safety is an issue.
All cumulative safety data will be reported to the DSMB
and reviewed on an ongoing basis throughout enrollment
and follow-up periods to ensure patient safety. Every effort
will be made to allow the DSMB to conduct an unbiased
review of patient safety information. All DSMB reports
will be made available to the appropriate agencies upon
request but will otherwise remain strictly confidential.
Clinical events adjudication committee (CEAC)
The clinical events adjudication committee (CEAC) is
comprised of interventional and non-interventional car-
diologists who are not participants in the study. The
CEAC is charged with the development of specific cri-
teria to be used for the categorization of clinical events
and clinical endpoints in the study, which are based on
protocol. At the outset of the trial, the CEAC will estab-
lish explicit rules outlining the minimum amount of
dates required and the algorithm to be followed in order
to classify a clinical event. All members of the CEAC
will be blinded to the primary results of the trial.
The CEAC will meet regularly to review and adjudi-
cate all clinical events in which the required minimum
data is available. The Committee will also review and
rule on all deaths that occur throughout the trial.
Ethical approval
This study has been approved by the institutional review
board of Inha University Hospital.
Discussion
Although prompt reperfusion treatment restores normal
epicardial flow, microvascular dysfunction may persist in
some patients with ACS [20,21]. The presence of micro-
vascular dysfunction is considered a poor prognostic fac-
tor in patients with ACS [22-24].
Impaired myocardial perfusion is caused by intra-
luminal platelets, fibrin thrombi, neutrophil plugging,
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tial edema and intramural hemorrhage [6-8]. There
have been a number of studies in patients with ACS in
which the use of antiplatelet agents and vasodilators
attenuated myocardial damage [9,10,25-28]. Such findings
strongly support the contribution of thrombotic and vaso-
constrictor mechanisms leading to the development of im-
paired microcirculation. Antiplatelet agents play a relevant
role in protecting against thrombus microembolization.
Recently the novel antiplatelet agents, ticagrelor and
prasugrel, have exhibited greater, more rapid and more
consistent platelet inhibition than clopidogrel. Ticagrelor
is a non-thienopyridine, direct P2Y12 blocker that is
more potent than clopidogrel and is associated with less
inter-individual variability. In the PLATO trial, ticagrelor
was found to be superior to clopidogrel with respect
to cardiovascular outcomes and total mortality without
increasing the risk of bleeding [2].
The dual antiplatelet regimen including aspirin and
clopidogrel has been used as the standard antiplatelet
modality in patients with ACS; however, clopidogrel has
several negative features. For example, the phenomenon
of the variability of response to clopidogrel, causing ele-
vated platelet reactivity, is seen in approximately 15 to
30% of patients, and it has been linked to ischemic events
including stent thrombosis after PCI. Another issue is the
delayed onset of action [29-31] that may be observed with
clopidogrel treatment. These drawbacks have led to the
development of more potent and rapid-acting antiplate-
let agents. Compared with clopidogrel, ticagrelor causes
greater, faster and more consistent platelet inhibition [2].
Beside the potent effect of inhibition of platelet function,
ticagrelor has been demonstrated previously to increase
adenosine levels by inhibiting adenosine re-uptake at the
tissue level and inducing ATP release from human red
blood cells, which stimulate vasodilation [4]. In addition, a
recent in vivo study in patients with ACS showed a sig-
nificant increase in adenosine plasma concentration in
patients treated with ticagrelor. In previous studies,
adenosine has shown multiple mechanisms affecting
platelet function, vessel tone and microcirculation. Adeno-
sine inhibits platelet aggregation through the activation of
adenosine 2A receptors and also dilates coronary micro-
vessels through the activation of adenosine 2A receptors,
which are strongly implicated in the regulation of coron-
ary blood flow [32,33]. However, the role of adenosine in
protecting the ischemic heart remains controversial and
the long-term impact of high plasma adenosine con-
centration on coronary artery disease remains to be de-
termined [34]. These properties of adenosine may be
particularly important in the context of diseased vessels
and the ischemia associated with ACS.
Consequently, based on the potent antiplatelet effect
and pleiotropic properties mediated by the increasedadenosine, we postulate that ticagrelor will reduce the
microvascular dysfunction in patients with ACS com-
pared with clopidogrel. Therefore, we designed a clinical
study that will evaluate the protective effect on micro-
vascular dysfunction of ticagrelor compared with clopi-
dogrel in patients with STEMI and NSTEMI.
Trial status
Enrollment into the TIME trial started in September




 Patients with STEMI or NSTEMI with documented
ischemia due to a significant lesion in a native
coronary artery
 Patients eligible for coronary revascularization
through PCI
 Patients must be ≥18 years of age
 Patients who are mentally and linguistically able to
understand the aim of the study and show sufficient
compliance in following the study protocol
 Patients are able to verbally acknowledge an
understanding of the associated risks, benefits and
treatment alternatives to therapeutic options of this
trial. The patients, by providing informed consent,
agree to these risks and benefits as stated in the
patient informed consent document.
Appendix B
Exclusion criteria:
 Unprotected left main artery
 Culprit lesion at side branch
 Stent thrombosis
 High-degree atrioventricular block
 Cardiogenic shock
 Cardiac arrest
 Contraindication to adenosine
 Pregnancy
 History of cerebrovascular accident or myocardial
infarction within 1 year.
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